AbCellera Biologics (ABCL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed judgment of validity of its US patent 10,087,408, which is directed to microfluidic devices used for culturing and selectively recovering cells.
The patent was challenged by Bruker Cellular Analysis, a subsidiary of Bruker (BRKR), which alleged invalidity based on "anticipation and obviousness over the prior art," the company said. However, Bruker's arguments were rejected by the US Patent Trial and Appeal Board.
AbCellera's patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the US District Court for the Northern District of California.
Bruker didn't immediately respond to a request for comment from MT Newswires.
Price: 2.07, Change: +0.04, Percent Change: +1.72
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。